Antibodies against ramp3

Abstract

Isolated antibodies capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor wherein the antibodies are of IgG, IgA or IgM isotype are provided, together with nucleic acid molecules encoding such antibodies, vectors comprising such nucleic acid molecules, host cells comprising such vectors, and methods of making the disclosed antibodies using such host cells. Also provided are compositions including the disclosed antibodies and methods of treating disorders, such as tumors, inflammatory disorders, cardiovascular disorders and osteoporosis, by administering such compositions.

We claim: 
     
         1 . An isolated antibody, or antigen binding fragment thereof, capable of binding a receptor activity modifying protein (RAMP) of CRLR, wherein the antibody, or antigen binding fragment thereof, is of IgG, IgA or IgM isotype. 
     
     
         2 . An isolated antibody, or antigen binding fragment thereof, of  claim 1 , wherein the antibody, or antigen binding fragment thereof, is capable of binding RAMP3. 
     
     
         3 . An isolated antibody, or antigen binding fragment thereof, capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor, wherein the antibody, or antigen binding fragment thereof, comprises a binding domain selected from the group consisting of:
 i) a binding domain comprising an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 95% identity to SEQ ID NO: 2;   ii) a binding domain comprising an amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 95% identity to SEQ ID NO: 4;   iii) a binding domain comprising an amino acid sequence of SEQ ID NO: 6 or an amino acid sequence having at least 95% identity to SEQ ID NO: 6; and   iv) a binding domain comprising an amino acid sequence of SEQ ID NO: 8 or an amino acid sequence having at least 95% identity to SEQ ID NO: 8.   
     
     
         4 . An isolated antibody, or antigen binding fragment thereof, capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor, wherein the antibody, or antigen binding fragment thereof, comprises a binding domain selected from the group consisting of:
 i) a binding domain comprising an amino acid sequence of SEQ ID NO: 10 or an amino acid sequence having at least 95% identity to SEQ ID NO: 10;   ii) a binding domain comprising an amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having at least 95% identity to SEQ ID NO: 12;   iii) a binding domain comprising an amino acid sequence of SEQ ID NO: 14 or an amino acid sequence having at least 95% identity to SEQ ID NO: 14; and   iv) a binding domain comprising an amino acid sequence of SEQ ID NO: 16 or an amino acid sequence having at least 95% identity to SEQ ID NO: 16.   
     
     
         5 . An isolated antibody, or antigen binding fragment thereof, of  claim 1 , wherein the antibody, or antigen binding fragment thereof, comprises at least one of the following binding domains:
 i) a binding domain comprising an amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 95% identity to SEQ ID NO: 4; and   ii) a binding domain comprising an amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having at least 95% identity to SEQ ID NO: 12.   
     
     
         6 . An isolated antibody, or antigen binding fragment thereof, of  claim 1 , wherein the antibody, or antigen binding fragment thereof, comprises at least one the following binding domains:
 i) a binding domain comprising an amino acid sequence of SEQ ID NO: 6 or an amino acid sequence having at least 95% identity to SEQ ID NO: 6; and   ii) a binding domain comprising an amino acid sequence of SEQ ID NO: 14 or an amino acid sequence having at least 95% identity to SEQ ID NO: 14.   
     
     
         7 . An isolated antibody, or antigen binding fragment thereof, of  claim 1 , wherein the antibody, or antigen binding fragment thereof, comprises at least one the following binding domains:
 i) a binding domain comprising an amino acid sequence of SEQ ID NO: 8 or an amino acid sequence having at least 95% identity to SEQ ID NO: 8; and   ii) a binding domain comprising an amino acid sequence of SEQ ID NO: 16 or an amino acid sequence having at least 95% identity to SEQ ID NO: 16.   
     
     
         8 . A composition comprising an antibody, or antigen binding fragment thereof, of  claim 1  and a pharmaceutically acceptable excipient, diluent, carrier, buffer or stabilizer. 
     
     
         9 . The composition of  claim 8 , further comprising an active agent. 
     
     
         10 . The composition of  claim 9 , wherein the active agent is a chemotherapeutic agent, a cytotoxic agent or a pain relief drug. 
     
     
         11 . A method for the treatment of a tumor in a patient comprising administering to the patient an effective amount of the pharmaceutical composition of  claim 8 . 
     
     
         12 . The method of  claim 11 , wherein the tumor is selected from the group consisting of:
 osteosarcomas, adenocarcinomas, intracranial tumors, prostate tumors, breast tumors, colon tumors, bone tumors and mesothelioma.   
     
     
         13 . The method of  claim 12 , wherein the tumor is a glioblastoma. 
     
     
         14 . A method for the treatment of an inflammatory disorder in a patient comprising administering to said patient an effective amount of the pharmaceutical composition of  claim 8 . 
     
     
         15 . A method for the treatment of a cardiovascular condition in a patient comprising administering to said patient an effective amount of the pharmaceutical composition of  claim 8 . 
     
     
         16 . A method for the treatment of osteoporosis in a patient comprising administering to said patient an effective amount of the pharmaceutical composition of  claim 8 . 
     
     
         17 . An isolated nucleic acid molecule encoding an antibody, or antigen binding fragment thereof, of  claim 1 . 
     
     
         18 . A vector comprising the isolated nucleic acid molecule of  claim 17 . 
     
     
         19 . An isolated host cell comprising the vector of  claim 18 . 
     
     
         20 . A method of producing an antibody, or antigen binding fragment thereof, comprising culturing the host cell of  claim 19  under conditions suitable for expression of the nucleic acid molecule encoding the antibody or antigen binding fragment thereof, and isolating the antibody or antigen binding fragment thereof produced by the host cell.